Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for its abbreviated new drug application for Vancomycin hydrochloride capsules, USP, 125mg and 250mg.
Subscribe to our email newsletter
The company has begun the shipment of the product which is indicated for the treatment of C difficile-associated diarrhea and also for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
The product is the generic version of ViroPharma’s VANCOCIN HCl capsules.
According to IMS Health, VANCOCIN HCl capsules had total US sales of $332m for the twelve months ending 29 February 2012.